Slate Medicines, a newly launched biotechnology company based in Raleigh, North Carolina, has closed a $130 million Series A financing round to advance its lead candidate, SLTE-1009, a monoclonal antibody targeting PACAP for the prevention of migraine and other headache disorders. The funding, co-led by RA Capital Management, Forbion, and Foresite Capital, coincides with the in-licensing of the Phase 1-ready asset from DartsBio Pharmaceuticals. Led by seasoned executives including CEO Gregory Oakes, the company aims to address unmet needs in migraine prevention through a novel mechanism that could offer superior convenience and efficacy for patients not adequately served by existing treatments.
Slate Medicines Emerges as a Key Player in Headache Therapeutics with Major Funding and Novel Anti-PACAP Approach
Slate Medicines has burst onto the biotech scene with a substantial $130 million Series A round, positioning the company to accelerate development of innovative therapies specifically designed for migraine prevention and related headache conditions. This financing comes at a time when the migraine market continues to evolve rapidly, driven by growing recognition of the limitations in current preventive options.
The company’s lead program centers on SLTE-1009 (previously known as DS009), a monoclonal antibody that selectively targets pituitary adenylate cyclase-activating polypeptide, or PACAP. PACAP is a neuropeptide implicated in the pathophysiology of migraine attacks. Research has shown that PACAP levels rise during migraine episodes, and blocking this pathway can interrupt the cascade of events leading to pain, photophobia, phonophobia, and other debilitating symptoms.
Unlike the dominant class of preventive migraine therapies that inhibit calcitonin gene-related peptide (CGRP) — such as monoclonal antibodies like erenumab, fremanezumab, galcanezumab, and eptinezumab — SLTE-1009 pursues a distinct biological target. While CGRP inhibitors have transformed care for many patients since their approvals beginning in 2018, a significant portion of individuals with episodic or chronic migraine experience incomplete response, intolerable side effects, or loss of efficacy over time. PACAP inhibition represents a promising orthogonal approach, potentially benefiting those who remain underserved.
SLTE-1009 was in-licensed from DartsBio Pharmaceuticals, a Guangdong-based biotech, and arrives Phase 1-ready, meaning the program is positioned for imminent entry into human clinical testing. The antibody has been engineered with features aimed at extending its half-life, which supports less frequent dosing and opens the door to convenient subcutaneous administration. This profile could enable at-home self-injection, improving patient adherence and accessibility compared to some intravenous or more frequent dosing regimens in the current market.
The migraine prevention landscape has seen substantial growth, with the global market for preventive therapies projected to expand as awareness increases and more patients seek long-term management options beyond acute treatments like triptans or gepants. Current CGRP-targeted monoclonals are administered monthly or quarterly via subcutaneous injection or infusion, offering strong efficacy for many but leaving room for innovation in mechanism, tolerability, and delivery.
Slate Medicines’ strategy focuses on leveraging this differentiated pathway to potentially deliver broader or more sustained benefits. Preclinical and early data supporting PACAP as a target have highlighted its role in trigeminal nerve activation and central sensitization — key processes in migraine generation. By neutralizing PACAP, SLTE-1009 aims to disrupt these mechanisms upstream or in parallel to CGRP signaling.
The $130 million raise provides ample runway to advance SLTE-1009 through Phase 1 studies assessing safety, pharmacokinetics, and preliminary pharmacodynamics in healthy volunteers and potentially migraine patients. Subsequent phases would evaluate efficacy in larger migraine populations, including those with episodic and chronic forms, as well as exploratory work in cluster headache or other PACAP-related headache disorders.
Leadership at Slate brings deep expertise in neurology, biotech operations, and commercial execution. Gregory Oakes serves as CEO and board director, drawing on over 30 years in biopharma, including leadership roles in clinical-stage and commercial organizations. Neil Buckley, formerly a venture partner, steps in as Chief Operating Officer and President. Roger Cady, Chief Medical Officer, is a recognized headache specialist with prior executive experience at companies that developed CGRP therapies.
The financing was co-led by prominent life sciences investors RA Capital Management, Forbion, and Foresite Capital, with participation from an additional undisclosed biotech-focused investor. In connection with the round, board seats were added for representatives from each lead firm: Andrew Levin from RA Capital, Tim Lohoff from Forbion, and Cindy Xiong from Foresite Capital.
This capital infusion reflects strong confidence in the PACAP pathway’s potential and the team’s ability to execute. The company emerged from efforts involving RA Capital’s Sera Medicines, a biologics accelerator, underscoring a deliberate build around high-conviction science in an area with clear clinical need.
Key Program Details: SLTE-1009 at a Glance
Target: Pituitary adenylate cyclase-activating polypeptide (PACAP)
Mechanism: Monoclonal antibody designed to neutralize PACAP and inhibit migraine-triggering pathways
Differentiation: Novel target distinct from CGRP; engineered for extended half-life and subcutaneous delivery
Development Stage: Phase 1-ready, in-licensed from DartsBio Pharmaceuticals
Indications: Prevention of migraine; potential expansion to other headache disorders
Administration Potential: Convenient at-home subcutaneous dosing
With this funding and asset in hand, Slate Medicines is set to generate critical clinical data that could validate PACAP blockade as a viable new pillar in migraine prevention. The company’s progress will be closely watched by patients, clinicians, and investors alike as it navigates the path toward proving whether this approach can deliver meaningful advances in a competitive and high-need therapeutic space.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, medical advice, or recommendations. Biotech investments involve significant risks, and drug development outcomes are uncertain.